JUNS JUPITER NEUROSCIENCES, INC.

Nasdaq jupiterneurosciences.com


$ 1.19 $ -0.05 (-4.07 %)    

Friday, 21-Nov-2025 14:19:03 EST
QQQ $ 590.61 $ 4.40 (0.75 %)
DIA $ 462.69 $ 5.05 (1.1 %)
SPY $ 659.17 $ 6.50 (1 %)
TLT $ 89.49 $ 0.27 (0.3 %)
GLD $ 373.59 $ -0.58 (-0.15 %)
$ 1.18
$ 1.24
$ 1.17 x 100
$ 1.22 x 97
$ 1.19 - $ 1.26
$ 0.51 - $ 19.51
64,844
na
41.87M
$ -0.36
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-18-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-28-2025 12-31-2024 10-K
5 12-23-2024 09-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jupiter-neurosciences-launches-nugevia-mnd-to-boost-cognitive-health-using-resveratrol-and-novasol-curcumin

MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuropro...

 jupiter-neurosciences-highlights-jotrol

JOTROL™ is currently advancing toward a Phase IIa trial in Parkinson's Disease, following breakthrough preclinical data in ...

 jupiter-neurosciences-unveils-nugevia-pwr-to-meet-demand-for-clinically-validated-longevity-supplements-commercial-availability-expected-in-fall-2025

PWR delivers science-driven cellular energy and recovery support as part of Jupiter's expanding longevity supplement portfo...

 jupiter-neurosciences-commercially-launches-nugevia-first-consumer-products-roll-out-in-q3-2025

First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's ev...

 jupiter-neurosciences-highlights-upcoming-milestones-in-shareholder-letter-including-lead-clinical-asset-jotrol-into-a-phase-2a-clinical-trial-in-parkinsons-disease

Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION